多发性骨髓瘤患者化疗给药流程优化的效果研究

Effect of drug administration process optimization in patients with chemotherapy for multiple myeloma

  • 摘要:
    目的 研究给药流程对多发性骨髓瘤化疗患者舒适度、耐受性和不良事件的影响。
    方法 选取多发性骨髓瘤化疗患者113例,随机分为对照组56例和观察组57例,对照组采用常规给药流程,观察组采用优化设计的给药流程行硼替佐米皮下注射。比较2组患者干预前后的舒适度、耐受性、不良事件及注射满意率。
    结果 干预后观察组舒适状况量表(GCQ)生理(24.59±2.73)分、心理(25.64±2.29)分、社会文化(22.64±2.05)分、环境(11.79±1.37)分及总分(79.21±6.81)分别高于对照组的(21.68±2.67)分、(22.05±2.16)分、(18.11±1.74)分、(9.42±1.46)分及(63.52±6.34)分; 观察组化疗总疗程(6.02±1.08)个,少于对照组的(7.86±1.59)个,化疗中断率8.77%低于对照组的37.5%, 足量足周期同步化疗率96.49%高于对照组的82.14%; 观察组给药期间不良事件(肝肾功能损伤、血小板减少症及周围神经病变)总发生率3.51%低于对照组的16.07%; 观察组注射满意率为94.74%, 高于对照组的78.57%; 2组各项指标比较差异均有统计学意义(P < 0.05)。
    结论 给药流程优化有利于提升多发性骨髓瘤化疗患者的舒适度和耐受性,减少不良反应的发生,且注射满意率高。

     

    Abstract:
    Objective To investigate the impacts of drug administration processes on comfort, tolerability and adverse events in patients with chemotherapy for multiple myeloma.
    Methods A total of 113 patients with chemotherapy for multiple myeloma were randomly divided into control group (n=56) and observation group (n=57). The control group was treated with conventional drug administration procedures, while the observation group was treated with bortezomib subcutaneously by an optimized drug administration process. Comfort level, tolerability, adverse events and satisfaction rate for injection were compared between the two groups before and after intervention.
    Results After intervention, the observation group scored higher on the General Comfort Questionnaire (GCQ) for physiological dimension of (24.59±2.73), psychological dimension of (25.64±2.29), sociocultural dimension of (22.64±2.05), environmental of (11.79±1.37), and total score of (79.21±6.81) than (21.68±2.67), (22.05±2.16), (18.11±1.74), (9.42±1.46) and (63.52±6.34) respectively in the control group. Total chemotherapy course was (6.02±1.08) cycles in the observation group, which was less than (7.86±1.59) cycles in the control group, with a chemotherapy discontinuation rate of 8.77% versus 37.5%, and the full-dose and full-schedule chemotherapy completion rate of 96.49% versus to 82.14% between observation group and control group, and all the differences were statistical significant (P < 0.05). The overall incidence of liver-kidney function damage, thrombocytopenia, and peripheral neuropathy during medication administration was 3.51% in the observation group, which was significantly lower than 16.07% in the control group (P < 0.05). The satisfaction rate for injection in the observation group was 94.74%, which was significantly higher than 78.57% in the control group (P < 0.05).
    Conclusion Optimizing the drug administration process can improve patient's comfort and tolerability during chemotherapy for multiple myeloma, reduce the incidence rate of adverse reactions, and has a high satisfaction rate for injection.

     

/

返回文章
返回